NOVATO, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Christopher M. Starr, Ph.D., Raptor's CEO, will present an overview of the company at the JMP Securities Healthcare Conference in New York. Raptor's presentation will take place on Wednesday, July 10, 2013 beginning at 1:30 p.m. EDT/10:30 a.m. PDT.
A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. is a biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company's first product, PROCYSBI™ (cysteamine bitartrate) delayed-release capsules, has been approved by the FDA, and recommended for marketing authorization by the European Committee for Medicinal Products for Human Use (CHMP) for the management of nephropathic cystinosis, a rare metabolic lysosomal storage disease. Raptor's pipeline also includes RP103 in a Phase 2/3 trial for Huntington's disease and a Phase 2 trial in nonalcoholic fatty liver disease in children. PROCYSBI has orphan designation for nephropathic cystinosis in the U.S. and EU and RP103 has received U.S. orphan drug designation for Huntington's disease. For additional information, please visit www.raptorpharma.com.
CONTACT: Georgia Erbez Chief Financial Officer Raptor Pharmaceutical Corp. (415) 408-6231 firstname.lastname@example.org INVESTOR CONTACTS: Westwicke Partners, LLC Stefan Loren, Ph.D. Managing Director (443) 213-0507 email@example.com Robert H. Uhl Managing Director (858) 356-5932 firstname.lastname@example.org MEDIA CONTACT: Carolyn Hawley Canale Communications (619) 849-5375 email@example.com
Source:Raptor Pharmaceutical Corp.